KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Receivables (2016 - 2024)

CRISPR Therapeutics AG (CRSP) has disclosed Receivables for 10 consecutive years, with $27.1 million as the latest value for Q4 2024.

  • Quarterly Receivables fell 86.88% to $27.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $27.1 million through Dec 2024, down 86.88% year-over-year, with the annual reading at $27.1 million for FY2024, 86.88% down from the prior year.
  • Receivables hit $27.1 million in Q4 2024 for CRISPR Therapeutics AG, down from $206.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $206.5 million in Q4 2023 to a low of $49000.0 in Q3 2022.
  • Historically, Receivables has averaged $29.0 million across 5 years, with a median of $10.8 million in 2020.
  • Biggest five-year swings in Receivables: crashed 99.7% in 2021 and later soared 105960.61% in 2023.
  • Year by year, Receivables stood at $10.8 million in 2020, then dropped by 19.73% to $8.7 million in 2021, then grew by 28.66% to $11.2 million in 2022, then soared by 1743.75% to $206.5 million in 2023, then crashed by 86.88% to $27.1 million in 2024.
  • Business Quant data shows Receivables for CRSP at $27.1 million in Q4 2024, $206.5 million in Q4 2023, and $70.0 million in Q2 2023.